Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Infinity Pharmaceuticals revenue
Infinity Pharmaceuticals's revenue is $2.6 million.
What is Infinity Pharmaceuticals's revenue?
- Infinity Pharmaceuticals's revenue growth from 2010 to 2022 is -96.36%.
- Infinity Pharmaceuticals has 100 employees, and the revenue per employee ratio is $25,930.
- Infinity Pharmaceuticals's peak quarterly revenue was $160.6M in 2014(q3).
- Infinity Pharmaceuticals peak revenue was $165.0M in 2014.
- Infinity Pharmaceuticals annual revenue for 2021 was 1.9M, 8.09% growth from 2020.
- Infinity Pharmaceuticals annual revenue for 2022 was 2.6M, 39.56% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Infinity Pharmaceuticals historical revenue
Infinity Pharmaceuticals's peak revenue was $165.0M in 2014. The peak quarterly revenue was $160.6M in 2014(q3).
Infinity Pharmaceuticals's revenue increased from $71.3m in 2010 to $2.6M currently. That's a -96.36% change in annual revenue.
Infinity Pharmaceuticals annual revenue
Infinity Pharmaceuticals annual revenue over time
| Fiscal year / year | Infinity Pharmaceuticals revenue |
|---|---|
| 2010 | $71.3M |
| 2011 | $92.8M |
| 2012 | $47.1M |
| 2014 | $165.0M |
| 2015 | $109.1M |
| 2016 | $18.7M |
| 2017 | $6.0M |
| 2018 | $22.1M |
| 2019 | $3.0M |
| 2020 | $1.7M |
| 2021 | $1.9M |
| 2022 | $2.6M |
How accurately did Infinity Pharmaceuticals' revenue projections match actual performance?
Infinity Pharmaceuticals annual growth
Infinity Pharmaceuticals saw the greatest revenue growth in 2018, when revenue increased by 269.1%.
Infinity Pharmaceuticals had the lowest revenue growth in 2019, when revenue changed by -86.23%.
Infinity Pharmaceuticals annual growth rate over time
| Year | Infinity Pharmaceuticals growth |
|---|---|
| 2011 | 30%↑ |
| 2012 | -49%↓ |
| 2014 | 250%↑ |
| 2015 | -34%↓ |
| 2016 | -83%↓ |
| 2017 | -68%↓ |
| 2018 | 269%↑ |
| 2019 | -86%↓ |
| 2020 | -44%↓ |
| 2021 | 8%↑ |
| 2022 | 40%↑ |
Infinity Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Infinity Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2011 | - | $20.0M | $23.3M | $22.3M |
| 2012 | $25.2M | $21.9M | - | - |
| 2014 | - | - | $160.6M | $4.4M |
| 2015 | $4.4M | $4.9M | $90.7M | $9.1M |
| 2016 | $9.3M | $9.5M | - | - |
| 2017 | - | - | $6.0M | - |
| 2018 | - | - | $22.0M | $146,000 |
| 2019 | $2.1M | $257,000 | $343,000 | $308,000 |
| 2020 | $428,000 | $360,000 | $496,000 | $436,000 |
| 2021 | $467,000 | $512,000 | $428,000 | $451,000 |
| 2022 | $652,000 | $686,000 | $712,000 | $543,000 |
| 2023 | $731,000 | $583,000 | - | - |
Infinity Pharmaceuticals jobs nearby
Do you work at Infinity Pharmaceuticals?
Is Infinity Pharmaceuticals transparent about its revenue structure?
Infinity Pharmaceuticals financial information
| CEO | Adelene Q. Perkins |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 100 |
| Date Founded | 2001 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $2.6M |
| Net Income | -$44,369,000 |
| PE Ratio | -2.41 |
| Tax Rate | 0.0% |
| Market Capitalization | $106.9M |
| Total Assets | $42,151,000 |
| Ticker | INFI |
Infinity Pharmaceuticals jobs you might like
Infinity Pharmaceuticals financing
Infinity Pharmaceuticals received early financing of $70.0M on 2002-06-24.
| Series | Round size | Date |
|---|---|---|
| Series B | $70M | 06/2002 |
| Series Unknown | $25M | 01/2004 |
| Series Unknown | $75M | 11/2008 |
| Post Ipo Debt | $50M | 11/2011 |
| Post Ipo Equity | $27.5M | 07/2012 |
| Post Ipo Equity | $78.5M | 09/2012 |
| Post Ipo Debt | $100M | 04/2014 |
| Post Ipo Equity | $20M | 01/2020 |
| Post Ipo Equity | $92M | 02/2021 |
Infinity Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Novartis Venture Fund | Series B |
| HBM Healthcare Investments AG | Series B |
| Wellcome Trust | Series B |
| Vulcan Medical Ventures | Series B |
| Steven Holtzman | Series B |
| Lotus BioScience Ventures | Series B |
| Stelios Papadopoulos | Series B |
| Prospect Venture Partners | Series B |
| Venrock | Series B |
| ALEXANDRIA REAL ESTATE EQUITIES, INC. | Series B |
| Frank Moss | Series B |
| Advent Life Sciences LLP | Series B |
| Amgen | Series Unknown |
| Purdue Pharma | Series Unknown |
| Mundipharma | Post Ipo Debt |
| Purdue Pharma | Post Ipo Equity |
| Deerfield | Post Ipo Debt |
| BVF PARTNERS L P | Post Ipo Equity |
Infinity Pharmaceuticals revenue FAQs
Search for jobs
Infinity Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Infinity Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Infinity Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Infinity Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Infinity Pharmaceuticals. The data presented on this page does not represent the view of Infinity Pharmaceuticals and its employees or that of Zippia.
Infinity Pharmaceuticals may also be known as or be related to INFINITY PHARMACEUTICALS, INC., Infinity Pharmaceuticals, Infinity Pharmaceuticals Inc and Infinity Pharmaceuticals, Inc.